Top

Published in:

05-01-2024 | ß-Blockers | Review

Beta-blocker adjunct therapy as a prospective anti-metastatic with cardio-oncologic regulation

Authors: Sachin G Nair, Sonu Benny, Wesley M Jose, Aneesh T P

Published in: Clinical & Experimental Metastasis | Issue 1/2024

Abstract

The prevailing treatment stratagem in cancer therapy still challenges the dilemma of a probable metastatic spread following an initial diagnosis. Including an anti-metastatic agent demands a significant focus to overrule the incidence of treatment failures. Adrenergic stimulation underlying the metastatic spread paved the way for beta blockers as a breakthrough in repurposing as an anti-metastatic agent. However, the current treatment approach fails to fully harness the versatile potential of the drug in inhibiting probable metastasis. The beta blockers were seen to show a myriad of grip over the pro-metastatic and prognostic parameters of the patient. Novel interventions in immune therapy, onco-hypertension, surgery-induced stress, induction of apoptosis and angiogenesis inhibition have been used as evidence to interpret our objective of discussing the potential adjuvant role of the drug in the existing anti-cancer regimens. Adding weight to the relative incidence of onco-hypertension as an unavoidable side effect from chemotherapy, the slot for an anti-hypertensive agent is necessitated, and we try to suggest beta-blockers to fill this position. However, pointing out the paucity in the clinical study, we aim to review the current status of beta blockers under this interest to state how the drug should be included as a drug of choice in every patient undergoing cancer treatment.

Spano D, Heck C, De Antonellis P, Christofori G, Zollo M (2012) Molecular networks that regulate cancer metastasis. Semin Cancer Biol 22(3):234–249. https://doi.org/10.1016/j.semcancer.2012.03.006CrossRefPubMed

Wei R, Liu S, Zhang S, Min L, Zhu S Cellular and extracellular components in tumor microenvironment and their application in early diagnosis of cancers. Anal Cell Pathol (Amst). 2020;2020:6283796. Published 2020 Jan 8. https://doi.org/10.1155/2020/6283796

Bakhoum SF, Cantley LC (2018) The multifaceted role of chromosomal instability in cancer and its microenvironment. Cell 174(6):1347–1360. https://doi.org/10.1016/j.cell.2018.08.027CrossRefPubMedPubMedCentral

Essa H, Dobson R, Wright D, Lip GYH (2020) Hypertension management in cardio-oncology. J Hum Hypertens 34(10):673–681. https://doi.org/10.1038/s41371-020-0391-8CrossRefPubMedPubMedCentral

Parker AL et al (2022) Current challenges in metastasis research and future innovation for clinical translation. Clin Exp Metastasis 39(2):263–277. https://doi.org/10.1007/s10585-021-10144-5CrossRefPubMedPubMedCentral

Lu T, Zheng C, Fan Z (Dec. 2022) Cardamonin suppressed the migration, invasion, epithelial mesenchymal transition (EMT) and lung metastasis of colorectal cancer cells by down-regulating ADRB2 expression. Pharm Biol 60(1):1011–1021. https://doi.org/10.1080/13880209.2022.2069823

Zhou Z et al (2022) Stress-induced epinephrine promotes epithelial-to-mesenchymal transition and stemness of CRC through the CEBPB/TRIM2/P53 axis. J Transl Med 20(1):262. https://doi.org/10.1186/s12967-022-03467-8CrossRefPubMedPubMedCentral

Pal AK et al (2022) Metabolomics and EMT markers of breast cancer: A crosstalk and future perspective. Pathophysiology 29(2):200–222. https://doi.org/10.3390/pathophysiology29020017

Papadaki MA, Stoupis G, Theodoropoulos PA, Mavroudis D, Georgoulias V, Agelaki S (2019) ‘Circulating tumor cells with stemness and Epithelial-to-Mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer’. Mol. Cancer Ther 18(2):437–447. Feb. https://doi.org/10.1158/1535-7163.MCT-18-0584

10.

Ramesh V, Brabletz T, Ceppi P (2020) Targeting EMT in Cancer with Repurposed Metabolic Inhibitors. Trends in Cancer. 6(11):942–950, https://doi.org/10.1016/j.trecan.2020.06.005

11.

Kim T-H et al (2020) Beta-adrenergic signaling modulates cancer cell mechanotype through a Rhoa-Rock-Myosin II Axis. Biophys J 118(3):96a-97a. https://doi.org/10.1016/j.bpj.2019.11.688

12.

Barathova M et al (Nov. 2020) Impairment of Hypoxia-Induced CA IX by Beta-blocker propranolol-impact on progression and metastatic potential of Colorectal Cancer cells. Int J Mol Sci 21(22):8760. https://doi.org/10.3390/ijms21228760

13.

Xu J, Liao K, Yang X, Wu C, Wu W (2022) Correction to: using single-cell sequencing technology to detect circulating Tumor cells in solid tumors. Mol Cancer 21(1):100. https://doi.org/10.1186/s12943-022-01564-2CrossRefPubMedPubMedCentral

14.

Gandhi S et al (Jan. 2021) Phase I clinical trial of Combination Propranolol and Pembrolizumab in locally Advanced and metastatic Melanoma: Safety, Tolerability, and preliminary evidence of Antitumor Activity. Clin Cancer Res 27(1):87–95. https://doi.org/10.1158/1078-0432.CCR-20-2381

15.

Uno K et al (2022) Metastatic Voyage of Ovarian Cancer Cells in Ascites with the Assistance of Various Cellular Components. Int J Mol Sci 23(8):1–17. https://doi.org/10.3390/ijms23084383

16.

Digernes I et al (2018) Brain metastases with poor vascular function are susceptible to pseudoprogression after stereotactic radiation Surgery. Adv Radiat Oncol 3(4):559–567. https://doi.org/10.1016/j.adro.2018.05.005CrossRefPubMedPubMedCentral

17.

Follain G et al (2020) Fluids and their mechanics in tumour transit: shaping Metastasis. Nat Rev Cancer 20(2):107–124. https://doi.org/10.1038/s41568-019-0221-xCrossRefPubMed

18.

Lourenço C, Conceição F, Jerónimo C, Lamghari M, Sousa DM (2022) ‘Stress in metastatic breast cancer: To the bone and beyond’. Cancers 14(8). https://doi.org/10.3390/cancers14081881

19.

Campbell JP et al (Jul. 2012) Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLOS Biol 10(7):e1001363, [Online]. Available: https://doi.org/10.1371/journal.pbio.1001363

20.

Madel M-B, Elefteriou F (2021) ‘Mechanisms Supporting the Use of Beta-Blockers for the Management of Breast Cancer Bone Metastasis’. Cancers 13(12). https://doi.org/10.3390/cancers13122887

21.

Clément-Demange L, Mulcrone PL, Tabarestani TQ, Sterling JA, Elefteriou F (2018) β2ARs stimulation in osteoblasts promotes Breast cancer cell adhesion to bone marrow endothelial cells in an IL-1β and selectin-dependent manner. J Bone Oncol 13:1–10. https://doi.org/10.1016/j.jbo.2018.09.002CrossRefPubMedPubMedCentral

22.

Blasco MT, Espuny I, Gomis RR (2022) Ecology and evolution of dormant metastasis. Trends in Cancer 8(7):570–582. https://doi.org/10.1016/j.trecan.2022.03.002

23.

Decker AM et al (Jul. 2020) Adrenergic Blockade Promotes Maintenance of Dormancy in Prostate Cancer Through Upregulation of GAS6. Transl Oncol 13(7):100781. https://doi.org/10.1016/j.tranon.2020.100781

24.

Aguirre-Ghiso JA, Sosa MS (Mar. 2018) Emerging topics on disseminated Cancer Cell Dormancy and the paradigm of Metastasis. Annu Rev Cancer Biol 2(1):377–393. https://doi.org/10.1146/annurev-cancerbio-030617-050446

25.

Carnio S, Novello S, Papotti M, Loiacono M, Scagliotti GV (Oct. 2013) Prognostic and predictive biomarkers in early stage non-small cell Lung cancer: Tumor based approaches including gene signatures. Transl Lung cancer Res 2(5):372–381. https://doi.org/10.3978/j.issn.2218-6751.2013.10.05

26.

Uramoto H, Tanaka F (Aug. 2014) Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res 3(4). [Online]. Available: https://tlcr.amegroups.com/article/view/2053

27.

Lou F, Huang J, Sima CS, Dycoco J, Rusch V, Bach PB (2013) Patterns of recurrence and second primary Lung cancer in early-stage Lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg 145(1):75–82. https://doi.org/10.1016/j.jtcvs.2012.09.030CrossRefPubMed

28.

Omuro AMP et al (Jun. 2005) High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 103(11):2344–2348. https://doi.org/10.1002/cncr.21033

29.

Rouzier R et al (Sep. 2001) Primary chemotherapy for operable breast cancer: Incidence and Prognostic Significance of Ipsilateral Breast Tumor Recurrence After Breast-Conserving Surgery. J Clin Oncol 19(18):3828–3835. https://doi.org/10.1200/JCO.2001.19.18.3828

30.

Holmberg L et al (Apr. 2008) Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. JNCI J Natl Cancer Inst 100(7):475–482. https://doi.org/10.1093/jnci/djn058

31.

Mokadem I et al (2019) Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study. Gastric Cancer. 22(6):1263–1273. https://doi.org/10.1007/s10120-019-00956-6

32.

Ushijima T, Sasako M (2004) Focus on gastric cancer. Cancer Cell 5(2):121–125. https://doi.org/10.1016/S1535-6108(04)00033-9CrossRefPubMed

33.

Turkoz FP et al (Sep. 2014) Bone Metastasis from Gastric Cancer: The Incidence, Clinicopathological Features, and Influence on Survival jgc 14(3):164–172. https://doi.org/10.5230/jgc.2014.14.3.164

34.

Fischer R, Breidert M, Keck T, Makowiec F, Lohrmann C, Harder J (2012) Early recurrence of Pancreatic cancer after resection and during adjuvant chemotherapy. Saudi J Gastroenterol 18(2):118–121. https://doi.org/10.4103/1319-3767.93815CrossRefPubMedPubMedCentral

35.

Matsuda Y et al (Sep. 2019) Encapsulating fibrosis following neoadjuvant chemotherapy is correlated with outcomes in patients with pancreatic cancer. PLoS One 14(9):e0222155. [Online]. Available: https://doi.org/10.1371/journal.pone.0222155

36.

Lai ECS, Lo C-M, Fan S-T, Liu C-L, Wong J (1998) Postoperative Adjuvant Chemotherapy After Curative Resection of Hepatocellular Carcinoma: A Randomized Controlled Trial. Arch Surg 133(2):183–188. Feb. https://doi.org/10.1001/archsurg.133.2.183

37.

Machado NO, Chopra P (2009) Pancreatic Metastasis from renal carcinoma managed by whipple resection. A case report and literature review of metastatic pattern, surgical management and outcome. J Pancreas 10(4):413–418

38.

Giuliano AE, Feig S, Eilber FR (1984) Changing metastatic patterns of osteosarcoma. Cancer 54(10):2160–2164, Nov. https://doi.org/10.1002/1097-0142(19841115)54:10>2160::AID-CNCR2820541016<3.0.CO;2-P

39.

Duffner PK, Cohen ME (Sep. 1981) Extraneural metastases in childhood brain tumors. Ann Neurol 10(3):261–265. https://doi.org/10.1002/ana.410100311

40.

Geisler JP, Geisler HE (1995) Brain metastases in epithelial ovarian carcinoma. Gynecol Oncol 57(2):246–249. https://doi.org/10.1006/gyno.1995.1134CrossRefPubMed

41.

Mravec B, Horvathova L, Hunakova L (Oct. 2020) Neurobiology of Cancer: the role of β-Adrenergic receptor signaling in various Tumor environments. Int J Mol Sci 21(21):7958. https://doi.org/10.3390/ijms21217958

42.

Amit M et al (2020) Loss of p53 drives neuron reprogramming in Head and Neck cancer. Nature 578(7795):449–454. https://doi.org/10.1038/s41586-020-1996-3CrossRefPubMedPubMedCentral

43.

Chen H, Liu D, Guo L, Cheng X, Guo N, Shi M (Jan. 2018) Chronic psychological stress promotes lung metastatic colonization of circulating Breast cancer cells by decorating a pre-metastatic niche through activating β-adrenergic signaling. J Pathol 244(1):49–60. https://doi.org/10.1002/path.4988

44.

Yap A et al (Jul. 2018) Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies. Br J Anaesth 121(1):45–57. https://doi.org/10.1016/j.bja.2018.03.024

45.

Garona J, Alonso DF (2016) Perioperative biology in primary Breast cancer: selective targeting of vasopressin type 2 receptor using desmopressin as a novel therapeutic approach. Breast Cancer Res Treat 158(3):597–599. https://doi.org/10.1007/s10549-016-3899-4Epub 2016 Jul 8. PMID: 27393620CrossRefPubMed

46.

Pouya FD, Rasmi Y, Asl ER (2020) Role of neurotransmitters and neuropeptides in breast cancer metastasis. Biochem (Moscow), Suppl Ser A Membr Cell Biol. 14(2):107–116. https://doi.org/10.1134/S1990747820020142

47.

Shurin MR, Baraldi JH, Shurin GV (Feb. 2021) Neuroimmune regulation of surgery-associated metastases. Cells 10(2):454. https://doi.org/10.3390/cells10020454

48.

Kwak S-B et al (2022) Tumor regionalization after Surgery: roles of the Tumor microenvironment and neutrophil extracellular traps. Exp Mol Med 54:720–729. https://doi.org/10.1038/s12276-022-00784-2CrossRefPubMedPubMedCentral

49.

Shaashua L et al (Aug. 2017) Perioperative COX-2 and β-Adrenergic blockade improves metastatic biomarkers in Breast Cancer patients in a Phase-II randomized trial. Clin Cancer Res 23(16):4651–4661. https://doi.org/10.1158/1078-0432.CCR-17-0152

50.

Hiller J et al (Nov. 2019) Preoperative β-Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial. Clin Cancer Res 26:p. clincanres.2641.2019, https://doi.org/10.1158/1078-0432.CCR-19-2641

51.

Sivanesan S, Taskén KA, Grytli HH (2022) Association of β-Blocker use at Time of Radical Prostatectomy with rate of treatment for Prostate Cancer recurrence. JAMA Netw Open 5(1):E2145230. https://doi.org/10.1001/jamanetworkopen.2021.45230CrossRefPubMedPubMedCentral

52.

Sakamoto A, Yagi K, Okamura T, Harada T, Usuda J (2019) Perioperative Administration of an intravenous Beta-blocker landiolol hydrochloride in patients with Lung Cancer: a Japanese retrospective exploratory clinical study. Sci Rep 9(1):5217. https://doi.org/10.1038/s41598-019-41520-7CrossRefPubMedPubMedCentral

53.

Ba Z et al (2022) Risk Factors for the comorbidity of hypertension and renal cell carcinoma in the cardio-oncologic era and treatment for tumor-induced hypertension. Front Cardiovascular Med 9. [Online]. Available: https://www.frontiersin.org/articles/https://doi.org/10.3389/fcvm.2022.810262

54.

Ruf R, Yarandi N, Ortiz-Melo DI, Sparks MA (2021) Onco-hypertension: overview of Hypertension with anti- cancer agents. J Onco-Nephrology 5(1):57–69. https://doi.org/10.1177/23993693211001374CrossRef

55.

Dreyling M et al (2020) Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent Lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol vol 95(4):362–371. https://doi.org/10.1002/ajh.25711CrossRef

56.

Katsi V et al (2019) Arterial Hypertension in patients under antineoplastic therapy: a systematic review. J Hypertens vol 37:884–901. https://doi.org/10.1097/HJH.0000000000002006CrossRef

57.

Hassen LJ et al (2019) Hypertension in the Cardio-Oncology Clinic. Heart Fail Clin vol 15(4):487–495. https://doi.org/10.1016/j.hfc.2019.06.010CrossRef

58.

Izzedine H et al Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association vol. 21,11 (2006): 3038–3045. https://doi.org/10.1093/ndt/gfl507

59.

De Bono, Johann S et al (2011) Abiraterone and increased survival in metastatic Prostate cancer. New Engl J Med vol 364:1995–2005. https://doi.org/10.1056/NEJMoa1014618CrossRef

60.

Cohen JB et al (Mar. 2023) Cancer therapy–related hypertension: A scientific statement from the American heart association. Hypertension 80(3):e46–e57. https://doi.org/10.1161/HYP.0000000000000224

61.

Murphy L, Maloney K, Gore L, Blanchette E (Jan. 2022) Hypertension in Pediatric Acute Lymphoblastic Leukemia Patients: Prevalence, Impact, and Management Strategies. Integr Blood Press Control 15:1–10. https://doi.org/10.2147/IBPC.S242244

62.

Kooijmans ECM et al (2022) Hypertension in long-term childhood cancer survivors after treatment with potentially nephrotoxic therapy; DCCSS-LATER 2: renal study. Eur J Cancer 172:287–299. https://doi.org/10.1016/j.ejca.2022.05.038CrossRefPubMed

63.

Lipshultz SE, Franco VI, Miller TL, Colan SD, Sallan SE (2015) Cardiovascular Disease in adult survivors of childhood cancer. Annu Rev Med 66:161–176. https://doi.org/10.1146/annurev-med-070213-054849CrossRefPubMedPubMedCentral

64.

Shah P et al (Sep. 2019) Meta-analysis comparing usefulness of Beta blockers to preserve left ventricular function during anthracycline therapy. Am J Cardiol 124(5):789–794. https://doi.org/10.1016/j.amjcard.2019.05.046

65.

Pantziarka P, Bouche G, Sukhatme V, Meheus L, Rooman I, Sukhatme VP (2016) Repurposing drugs in oncology (ReDO) - Propranolol as an anti-cancer agent. Ecancermedicalscience 10:1–32. https://doi.org/10.3332/ecancer.2016.680

66.

Yang R, Zhang Y, Liao X, Yao Y, Huang C, Liu L (Dec. 2020) The Relationship Between Anti-Hypertensive Drugs and Cancer: Anxiety to be Resolved in Urgent. Front Pharmacol 11:610157. https://doi.org/10.3389/fphar.2020.610157

67.

Angell HK, Bruni D, Barrett JC, Herbst R, Galon J (Jan. 2020) The immunoscore: Colon Cancer and Beyond. Clin Cancer Res 26(2):332–339. https://doi.org/10.1158/1078-0432.CCR-18-1851

68.

Murugan S, Rousseau B, Sarkar DK (2021) Beta 2 adrenergic receptor antagonist propranolol and opioidergic receptor antagonist naltrexone produce Synergistic effects on Breast Cancer Growth Prevention by acting on Cancer cells and Immune Environment in a preclinical model of Breast Cancer. Cancers 13(19). https://doi.org/10.3390/cancers13194858

69.

Ann L, Coker, Nalawansha MK, Pflum DA (2017) 乳鼠心肌提取 HHS Public Access. Physiol Behav 176(5):139–148. https://doi.org/10.1615/CritRevImmunol.2019031188.Beta-adrenergicCrossRef

70.

Gardner KP et al (2022) Beta 2-Adrenergic receptor in circulating Cancer-Associated cells predicts for increases in stromal macrophages in circulation and patient survival in metastatic Breast Cancer. 1–11,

71.

Jensen AWP, Carnaz Simões AM, Thor P, Straten, Holmen Olofsson G (Jan. 2021) Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe? Cancers (Basel) 13(3):394. https://doi.org/10.3390/cancers13030394

72.

Mistro GD et al (2022) Focal adhesion kinase plays a dual role in TRAIL resistance and metastatic outgrowth of malignant Melanoma. Cell Death Dis 13(1). https://doi.org/10.1038/s41419-022-04502-8

73.

Batalla-Covello J, Ali S, Xie T, Amit M (2022) β-Adrenergic signaling in Skin cancer. FASEB BioAdvances 4(4):225–234. https://doi.org/10.1096/fba.2021-00097CrossRefPubMedPubMedCentral

74.

Sastry KSR et al (2007) Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. J Biol Chem 282:14094–14100. https://doi.org/10.1074/jbc.M611370200CrossRefPubMed

75.

Özler S, Pazarci P (2022) Anti-tumoral effect of beta-blockers on prostate and bladder cancer cells via mitogen-activated protein kinase pathways. Anticancer Drugs 33(4). [Online]. Available: https://journals.lww.com/anti-cancerdrugs/Fulltext/2022/04000/Anti_tumoral_effect_of_beta_blockers_on_prostate.6.aspx

76.

Armaiz-pena GN et al (2013) metastasis. https://doi.org/10.1038/ncomms2413.SrcCrossRef

77.

Pasquier E et al (2013) B-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. Br J Cancer 108(12):2485–2494. https://doi.org/10.1038/bjc.2013.205CrossRefPubMedPubMedCentral

78.

Erguven M et al (2010) Carvedilol in glioma treatment alone and with imatinib in vitro. Int J Oncol vol 36(4):857–866. https://doi.org/10.3892/ijo_00000563CrossRef

79.

Ann L, Coker, Nalawansha MK, Pflum DA (2017) 乳鼠心肌提取 HHS Public Access. Physiol Behav 176(5):139–148. https://doi.org/10.1158/0008-5472.CAN-17-1492.GenomicCrossRef

80.

Vincent-Chong VK, Seshadri M (2021) Adrenergic-Angiogenic Crosstalk in Head and Neck Cancer: Mechanisms and Therapeutic Implications. Front Oral Heal 2(June):1–7. https://doi.org/10.3389/froh.2021.689482

81.

Li X et al (2022) Targeting Tumor innervation: premises, promises, and challenges. Cell Death Discov 8(1):1–12. https://doi.org/10.1038/s41420-022-00930-9CrossRef

82.

Lamboy-Caraballo R, Ortiz-Sanchez C, Acevedo-Santiago A, Matta J, Monteiro ANA (2020) Armaiz-Pena, Norepinephrine-induced DNA damage in Ovarian cancer cells. Int J Mol Sci 21(6). https://doi.org/10.3390/ijms21062250

83.

Masjedi A et al (2018) The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. Biomed Pharmacother 108(September):1415–1424. https://doi.org/10.1016/j.biopha.2018.09.177

84.

Quốc Luong KV, Nguyên LTH (2012) The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms. Cancer Manag Res 4(1):431–445. https://doi.org/10.2147/CMAR.S39153CrossRefPubMed

85.

Rossi M et al (July 2022) Beta-blockers disrupt mitochondrial bioenergetics and increase radiotherapy efficacy independently of beta-adrenergic receptors in medulloblastoma. eBioMedicine 82. https://doi.org/10.1016/j.ebiom.2022.104149

86.

Perillo B et al (2020) ROS in cancer therapy: the bright side of the moon. Exp Mol Med 52(2):192–203. https://doi.org/10.1038/s12276-020-0384-2CrossRefPubMedPubMedCentral

87.

Ekestubbe L et al (2022) Pharmacological differences between beta-blockers and postoperative mortality following colon Cancer Surgery. Sci Rep 12(1):1–8. https://doi.org/10.1038/s41598-022-08736-6CrossRef

88.

Tewarie IA, Senders JT, Hulsbergen AFC, Kremer S, Broekman MLD (2021) Beta-blockers and glioma: a systematic review of preclinical studies and clinical results. Neurosurg Rev 44(2):669–677. https://doi.org/10.1007/s10143-020-01277-4CrossRefPubMed

89.

Erguven M et al (2010) Carvedilol in glioma treatment alone and with imatinib in vitro. Int J Oncol 36(4):857–866. https://doi.org/10.3892/ijo_00000563CrossRefPubMed

90.

Sokołowska P, Nowak JZ (2005) Constitutive activity of β-adrenergic receptors in C6 glioma cells. Pharmacol Rep 57(5):659–663PubMed

91.

Annabi B, Lachambre M-P, Plouffe K, Moumdjian R, Béliveau R (2009) Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res 60(5):438–445. https://doi.org/10.1016/j.phrs.2009.05.005CrossRefPubMed

92.

Alvarez-Breckenridge C et al (May 2022) Emerging systemic treatment perspectives on Brain metastases: moving toward a Better Outlook for patients. Am Soc Clin Oncol Educ B no. 42:147–165. https://doi.org/10.1200/EDBK_352320

93.

Fumagalli C, Maurizi N, Marchionni N, Fornasari D (2020) β-blockers: their new life from Hypertension to cancer and migraine. Pharmacol Res 151:104587. https://doi.org/10.1016/j.phrs.2019.104587CrossRefPubMed

94.

Rossi M et al (2022) Beta-blockers disrupt mitochondrial bioenergetics and increase radiotherapy efficacy independently of beta-adrenergic receptors in medulloblastoma. eBioMedicine 82:104149. https://doi.org/10.1016/j.ebiom.2022.104149

95.

Calvani M, Subbiani A, Bruno G, Favre C (2020) Beta-Blockers and Berberine: A Possible Dual Approach to Contrast Neuroblastoma Growth and Progression. Oxid Med Cell Longev. 7534693. https://doi.org/10.1155/2020/7534693

96.

Wei W-J, Shen C-T, Song H-J, Qiu Z-L, Luo Q-Y (2016) Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib. Oncol Rep 36(3):1576–1584. https://doi.org/10.3892/or.2016.4918CrossRefPubMed

97.

Sidorova M, Petrikaitė V (2022) The effect of Beta adrenoreceptor blockers on viability and cell colony formation of Non-small Cell Lung Cancer Cell Lines A549 and H1299. Molecules 27(6). https://doi.org/10.3390/molecules27061938

98.

Chaudhary KR et al (2019) Effects of β-Adrenergic antagonists on Chemoradiation Therapy for locally Advanced Non-small Cell Lung Cancer. J Clin Med 8(5). https://doi.org/10.3390/jcm8050575

99.

Nuevo-Tapioles C et al (Jul. 2020) Coordinate β-adrenergic inhibition of mitochondrial activity and angiogenesis arrest Tumor growth. Nat Commun 11(1):3606. https://doi.org/10.1038/s41467-020-17384-1

100.

Chang C-H et al (2020) Effect of β-Blocker in Treatment-Naïve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs. Front Oncol 10. [Online]. Available: https://www.frontiersin.org/articles/https://doi.org/10.3389/fonc.2020.583529

101.

Yang A et al (2021) Beta-blockers have no impact on survival in pancreatic ductal adenocarcinoma prior to cancer diagnosis. Sci Rep 11(1):1038. https://doi.org/10.1038/s41598-020-79999-0CrossRefPubMedPubMedCentral

102.

Zhang X et al (2019) Chronic stress promotes gastric cancer progression and Metastasis: an essential role for ADRB2. Cell Death Dis 10(11):788. https://doi.org/10.1038/s41419-019-2030-2CrossRefPubMedPubMedCentral

103.

Fjæstad KY et al (2022) Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment. Oncogene. 41(9):1364–1375. https://doi.org/10.1038/s41388-021-02170-0

104.

Joshi SS, Badgwell BD (May 2021) Current treatment and recent progress in gastric cancer. CA Cancer J Clin 71(3):264–279. https://doi.org/10.3322/caac.21657

105.

Li X et al (Mar. 2022) Targeting Tumor innervation: premises, promises, and challenges. Cell Death Discov 8(1):131. https://doi.org/10.1038/s41420-022-00930-9

106.

Chang P-Y et al (May 2019) The effect of propranolol on the prognosis of hepatocellular carcinoma: a nationwide population-based study. PLoS ONE 14(5):e0216828–e0216828. https://doi.org/10.1371/journal.pone.0216828

107.

Wijarnpreecha K et al (Aug. 2021) Nonselective beta-blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States. Aliment Pharmacol Ther 54(4):481–492. https://doi.org/10.1111/apt.16490

108.

Chang H, Lee SH (2022) Beta-adrenergic receptor blockers and hepatocellular carcinoma survival: a systemic review and meta-analysis. Clin Exp Med 1–12. https://doi.org/10.1007/s10238-022-00842-z

109.

Wang F et al (2018) Propranolol suppresses the proliferation and induces the apoptosis of Liver cancer cells. Mol Med Rep 17(4):5213–5221. https://doi.org/10.3892/mmr.2018.8476CrossRefPubMedPubMedCentral

110.

Altshuler E et al (2022) Impact of β-blockers on survival outcomes in patients with unresectable hepatocellular carcinoma. Hepatic Oncol 9(2). https://doi.org/10.2217/hep-2021-0010

111.

Fiala O et al (2021) Impact of Concomitant Cardiovascular Medication on Survival of metastatic renal cell carcinoma patients treated with Sunitinib or Pazopanib in the First line. Target Oncol 16(5):643–652. https://doi.org/10.1007/s11523-021-00829-yCrossRefPubMed

112.

Ribatti D, Annese T, Ruggieri S, Tamma R, Crivellato E (2019) Limitations of anti-angiogenic treatment of tumors. Transl Oncol 12:981–986. https://doi.org/10.1016/j.tranon.2019.04.022CrossRefPubMedPubMedCentral

113.

Assayag J, Pollak MN, Azoulay L (2014) Post-diagnostic use of beta-blockers and the risk of death in patients with Prostate cancer. Eur J Cancer 50(16):2838–2845. https://doi.org/10.1016/j.ejca.2014.08.006CrossRefPubMed

114.

Nagaraja AS, Sadaoui NC, Lutgendorf SK, Ramondetta LM, Sood AK (2013) Beta blockers: a new role in chemotherapy. Expert Opin Investig Drugs 22(11):1359–1363. https://doi.org/10.1517/13543784.2013.825250.BetaCrossRefPubMedPubMedCentral

115.

Hu Q et al (Aug. 2022) Propranolol suppresses bladder cancer by manipulating intracellular pH via NHE1. Transl Androl Urol 11(8). [Online]. Available: https://tau.amegroups.com/article/view/99287

116.

Udumyan R, Botteri E, Jerlstrom T, Montgomery S, Smedby KE, Fall K (Aug. 2022) Beta-blocker use and urothelial bladder cancer survival: a Swedish register-based cohort study. Acta Oncol (Madr) 61(8):922–930. https://doi.org/10.1080/0284186X.2022.2101902

117.

Choy C et al (2016) Inhibition of β2- adrenergic receptor reduces triple-negative Breast cancer brain metastases: the potential benefit of perioperative β-blockade. Oncol Rep 35(6):3135–3142. https://doi.org/10.3892/or.2016.4710CrossRefPubMedPubMedCentral

118.

Rains SL, Amaya CN, Bryan BA (2017) Beta-adrenergic receptors are expressed across diverse cancers. Oncoscience 4(7–8):95–105. https://doi.org/10.18632/oncoscience.357

119.

Montoya A et al (2019) The beta adrenergic receptor antagonist propranolol alters mitogenic and apoptotic signaling in late stage Breast cancer. Biomed J 42(3):155–165. https://doi.org/10.1016/j.bj.2019.02.003CrossRefPubMedPubMedCentral

120.

Pasquier E et al (2011) Propranolol potentiates the anti-angiogenic effects and antitumor efficacy of chemotherapy agents: Implication in breast cancer treatment. Oncotarget 2(10):797–809. https://doi.org/10.18632/oncotarget.343

121.

Solernó LM et al (2022) Propranolol blocks osteosarcoma cell cycle progression, inhibits angiogenesis and slows xenograft growth in combination with cisplatin-based chemotherapy. Sci Rep 12(1):15058. https://doi.org/10.1038/s41598-022-18324-3CrossRefPubMedPubMedCentral

122.

Solerno L et al (Aug. 2020) Abstract 3062: Drug repurposing of β-blocker propranolol and hemostatic compound desmopressin in osteosarcoma: Preclinical antitumor activity on 2D and 3D cell growth, chemotaxis and xenograft progression. Cancer Res 80(16_Supplement):3062. https://doi.org/10.1158/1538-7445.AM2020-3062

123.

Zhang Z, Tan X, Jiang Z, Wang H, Yuan H (2022) Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future. Front Pharmacol 13. [Online]. Available: https://www.frontiersin.org/articles/https://doi.org/10.3389/fphar.2022.1031527

124.

Porcelli L et al (2020) The β-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study. Sci Rep 10(1):10465. https://doi.org/10.1038/s41598-020-67342-6CrossRefPubMedPubMedCentral

125.

Embaby A, van Merendonk L, Steeghs N, Beijnen J, Huitema A (2022) Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose? Front Oncol 12. [Online]. Available: https://www.frontiersin.org/articles/https://doi.org/10.3389/fonc.2022.940582

126.

Diaz ES, Karlan BY, Li AJ (2012) Impact of beta blockers on epithelial Ovarian cancer survival. Gynecol Oncol 127(2):375–378. https://doi.org/10.1016/j.ygyno.2012.07.102CrossRefPubMed

127.

Hefner J, Csef H (Oct. 2016) The Clinical Relevance of Beta Blockers in Ovarian Carcinoma: A systematic review. Geburtshilfe Frauenheilkd 76(10):1050–1056. https://doi.org/10.1055/s-0042-115016

128.

Spilsbury K et al (Aug. 2022) Perioperative Beta-Blocker Supply and Survival in Women With Epithelial Ovarian Cancer and a History of Cardiovascular Conditions. J Clin Oncol. p. JCO.22.00097, https://doi.org/10.1200/JCO.22.00097

129.

Español P et al (2022) Neural plasticity of the uterus: New targets for endometrial cancer? Womens. Health (Lond. Engl) 18:17455057221095536–17455057221095536, https://doi.org/10.1177/17455057221095537

130.

Zhou J (Mar. 2022) PLUS : Predicting cancer metastasis potential based on positive and unlabeled learning. PLOS Comput Biol. 18(3):e1009956. [Online]. Available: https://doi.org/10.1371/journal.pcbi.1009956

Title: Beta-blocker adjunct therapy as a prospective anti-metastatic with cardio-oncologic regulation
Authors: Sachin G Nair
Sonu Benny
Wesley M Jose
Aneesh T P
Publication date: 05-01-2024
Publisher: Springer Netherlands
Keywords: ß-Blockers
Metastasis
Hypertension
Hypertension
Propranolol
Published in: Clinical & Experimental Metastasis / Issue 1/2024
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-023-10258-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Comparison of Gamma Knife (GK) and Linear Accelerator (LINAC) radiosurgery of brain metastasis resection cavity: a systematic review and proportional meta-analysis

Acetone compression improves lymph node yield and metastasis detection in colorectal cancer

Cutting-edge innovations in breast cancer diagnosis- the potential of HDMI biomarkers

Computational markers for personalized prediction of outcomes in non-small cell lung cancer patients with brain metastases

Clinical characteristics, treatment, and outcome of patients with large cell neuroendocrine carcinoma of the lung and brain metastases – data from a tertiary care center

Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance

Keynote webinar | Spotlight on antibody–drug conjugates in cancer